Morphology of tumor cell nuclei is significantly related with survival time of patients with glioblastomas

Clinical Cancer Research

Volumn 11, Issue 6, 2005, Pages 2141-2148

  Nafe, Reinhold ^a   Franz, Kea ^a   Schlote, Wolfgang ^a   Schneider, Berthold ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SURVIVAL; CELL NUCLEUS; CELL PROLIFERATION; CELL SHAPE; CELL SIZE; CELL SURVIVAL; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MORPHOMETRICS; PRIORITY JOURNAL; TUMOR CELL; TUMOR CLASSIFICATION;

ADULT; AGE DISTRIBUTION; AGED; BRAIN NEOPLASMS; CELL NUCLEUS; CELL PROLIFERATION; GLIOBLASTOMA; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 16844370829     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1198     Document Type: Article

References (32)

1. Scott JN, Rewcastle NB, Brasher PMA, et al. Which glioblastoma multiforme patient will become a long-term survivor? A population based study. Ann Neurol 1999;46:183-8.
2. Mineo JF, Quintin-Roue I, Lucas B, Buburusan V, Besson G. Glioblastomas: clinical study and search for prognostic factors. Neurochirurgie 2002;48:500-9.
3. Burton EC, Lamborn KR, Forsyth P, et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 2002;8:180-7.
4. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK. Glioblastoma. In: Kleihues P, Cavenee WK, editors. Pathology and genetics of tumours of the nervous system. Lyon (France): International Agency for Research on Cancer; 2000. p. 29-39.
5. Nafe R, Schlote W, Schneider B. Planimetric characterization of tumor cell nuclei in astrocytic tumors - comparison of different tumor grades according to the WHO classification. E J Pathol 2000;6:004-01.txt.
6. Nafe R, Schlote W, Schneider B. Shape analysis of tumor cell nuclei in ependymomas by means of Fourier-analysis. Anal Quant Cytol Histol 2000;22:475-82.
7. Nafe R, Glienke W, Schlote W, Schneider B. EGFR gene-amplification in glioblastomas - Is there a relationship with morphology of tumor cell nuclei and proliferative activity? Anal Quant Cytol Histol 2001;23:135-43.
8. Nafe R, Franz K, Schlote W, Schneider B. Quantitative investigation of nuclear morphology in glioblastomas and its relation to survival time. Clin Neuropathol 2003;22:129-36.
9. Nafe R, Schlote W. Densitometric analysis of tumor cell nuclei in low-grade and high-grade astrocytomas. E J Pathol 2002;8:023-02.txt.
10. Nafe R, Schlote W. Topometric analysis of diffuse astrocytomas. Anal Quant Cytol Histol 2003;25:12-8.
11. Haralick RM, Shanmugam K, Dinstein I. Textural features for image classification. IEEE Trans Syst Man Cybern 1973;3:610-21.
12. Nafe R, Schneider B. Data analysis for comparative histometry in pathology - I. Classification procedures and other statistical methods. E J Pathol 2000;6:002-03.txt.
13. Nafe R, Glienke W, Burgemeister R, et al. Regional heterogeneity of EGFR gene amplification and nuclear morphology in glioblastomas. Anal Quant Cytol Histol 2004;26:65-76.
14. Jacobs AH, Voges J, Kracht LW, et al. Imaging in gene therapy of patients with glioma. J Neurooncol 2003;65:291-305.
15. Trojan LA, Kopinski P, Mazurek A, et al. IGF-I triple helix gene therapy of rat and human gliomas. Rocz Akad Med Bialymst 2003:48:18-27.
16. Fine HA, Wen PY, Maher EA, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003;21:2299-304.
17. Martin H, Voss K. Automated image analysis of glioblastomas and other gliomas. Acta Neuropathol (Berl) 1982;58:9-16.
18. Martin H, Voss K. Computerized classification of gliomas by automated microscope picture analysis (AMPA). Acta Neuropathol (Berl) 1982;58:261-8.
19. Scarpelli M, Montironi R, Collan Y, et al. Malignant glial tumours: prognostic value of quantitative microscopy. Neurochirurgia 1989;32:135-40.
20. Schiebe M, Ohneseit P, Hoffmann W, Meyermann R, Rodemann HP, Bamberg M. Loss of heterozygosity at 11p15 and p53 alterations in malignant gliomas. J Cancer Res Clin Oncol 2001;127:325-8.
21. Schmidt MC, Antweiler S, Urban U, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002;61:321-8.
22. Nakatani K, Yoshimi N, Mori H, et al. The significance of the expression of tumor suppressor gene DCC in human gliomas. J Neurooncol 1998;40:237-42.
23. Hung KS, Howng SL. Prognostic significance of annexin VII expression in glioblastomas multiforme in humans. J Neurosurg 2003;99:886-92.
24. Kirla RM, Haapasalo HK, Kalimo H, Salminen E.K. Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer 2003;97:644-8.
25. Burger PC, Green SB. Patients age, histologic features and length of survival in patients with glioblastoma multiforme. Cancer 1987;59:1617-25.
26. Korshunov A, Golanov A, Sycheva R, Pronin I. Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases. J Clin Pathol 1999;52:574-80.
27. Birner P, Piribauer M, Fischer I, et al. Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 2003;13:133-43.
28. Barker FG, Davis RL, Chang SM, Prados MD. Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 1996;77:1161-6.
29. Baxedine-Jones J, Campbell I, Ellison D. P53 status has no prognostic significance in glioblastomas treated with radiotherapy. Clin Neuropathol 1997;16:332-6.
30. Birner P, Piribauer M, Fischer I, et al. Prognostic relevance of p53 protein expression in glioblastoma. Oncol Rep 2002;9:703-7.
31. Bouvier-Labit C, Chinot O, Ochi C, Gambarelli D, Dufor H, Figarella-Branger D. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol 1998;24:381-8.
32. Hwang SL, Hong YR, Chai CY, Lin HJ, Howng SL. Prognostic evaluation in supratentorial astrocytic tumors using p53, epidermal growth factor receptor, c-erb b-2 immunostaining. Kaohsiung J Med Sci 1998;14:607-15.